## **Pediatric Headaches**

James Miles, MD NDAFP Annual Meeting November 14th, 2025

2

## **Learning Objectives**

- Review the classification of pediatric headaches
- Appreciate when there is a need for further evaluation (red flags)
- Understand the differences between migraine presentation in children and adults
- Discuss migraine treatment, preventative and acute measures

# Classification

- Childhood headaches rarely caused by a serious underlying disorder
- Primary: Headache syndromes

3

- Can be exacerbated by secondary etiology
- New headaches could have underlying cause
- · Secondary: Underlying condition
  - Infectious illness most common cause of acute pediatric headache

#### **Disclosures**

Relevant Financial Relationship(s)
None

Off Label Usage None

Epidemiology

- >90% adolescents report having a headache (HA) by 18 years of age
- 17% kids 4-18 years report having notable recurrent HAs in the past 12 months
- More prevalent in girls after 12 years of age

Classification: Primary

- Migraine
- · Tension-type HA
- Cluster HAs

5

# Tension-Type Headaches

- Last 30 minutes to 7 days
- Bilateral location
- · Pressing or tightening
- · Mild to moderate intensity
- · Not aggravated by physical activity
- · No nausea or vomiting
- · No more than one of photo- or phonophobia
- Tx: similar to migraine

#### Cluster Headaches

- Severe unilateral orbital, supraorbital, and/or temporal pain lasting 15 to 180 minutes
- Conjunctival injection and/or lacrimation
- · Nasal congestion and/or rhinorrhea
- · Forehead and facial sweating
- · Miosis, ptosis, and/or eyelid edema
- Sense of restlessness or agitation
- Tx: 100% oxygen or sumatriptan 6 mg IM acutely, verapamil 240 mg daily preventative

# Classification: Secondary

- Acute febrile illness
  - Most common children
  - Recurrent rhinosinusitis most common misDx
- CNS infection
- Posttraumatic
- Hypertension

9

- Medication
- Medication overuse
- Brain tumor
- Hydrocephalus
- · Intracranial hemorrhage
- Idiopathic Intracranial Hypertension

**Evaluating the Patient** 

10

8

## Clinical Presentation: Younger Kids

- · Able to attenuate or ignore through play
- · Cry, rock, hide
- Chronic pain associated with anxiety, depression, and behavior problems
- · May affect ability to eat, sleep, or play

## History

- · Age of onset
  - Anything occur around time of onset?
  - Current triggers?
- Timing, frequency, and pattern
- Location
- · Characterizing headaches
  - Dull and achy vs. throbbing
  - "Draw the headache"
- Duration
- Severity

# History

- · Associated signs and symptoms
- · Previous evaluations
- · Headache hygiene
  - Sleep
  - Water
  - Diet
  - Activity
- Current and previous medications

## History

- · Pregnancy, labor and delivery, neonatal period
- · Growth and development
- Major surgeries or hospitalizations
- · Chronic illnesses or medications
- Academic performance
- Family History

13 14

# **Red Flags**

- · Young age
- Awakens in middle of night
- Occipital HAs
- Persisting, worsening HA
- "Worse HA of my life"
- New HA
- Recumbent position
- Valsalva maneuver
- · Resistant to treatment
- Chronic illness
- Abnormal neurologic exam

## **Physical Exam**

- Most sensitive indicator of needing further evaluation
- · Vital signs
  - Temperature
  - Blood pressure
  - Height and weight
  - Head circumference

15 16

## **Physical Exam**

- · General appearance
- Eyes, ears, nose, and throat
- Head and neck
- · Heart and Lungs
- Abdomen
- Skin
- Psychological status

Physical Exam: Neuro

- Mental status
- Cranial nerves
- Motor
- Sensation
- Reflexes
- Coordination
- Gait

# Diagnostics

- · MRI brain vs. CT head
  - Nonspecific T2 hyperintensities w/ migraine
- MRA vs. CTA
- LP: intracranial infection, subarachonoid hemorrhage, IIH
- CBC, toxicology, thyroid function tests
- · EEG not indicated

.

19 20

## Pathophysiology

- Polygenetic and multifactionial
- Cortical spreading depression
- Serotonin and central pain control pathways
- CGRP

## **Epidemiology**

Migraine Headaches

- Prevalence 2.5% <7 yrs, 5% by age 10
- Females>males after puberty
- Lower socioeconomic status associated with chronic migraine
- · Family history of migraine common
- 90% adults diagnosed with recurrent sinus HAs actually have migraine HAs

21 22

# Diagnostic Criteria

- At least 5 attacks
- Lasting 4-72 hrs (2-72 in children)
- At least 2 of the following:
  - Unilateral (bilateral in children)
  - Pulsating/throbbing
  - Moderate to severe pain
  - Aggravation or causing avoidance of physical activity
- At least one of the following:
  - Nausea and/or vomiting
  - Photophobia and phonophobia (behavioral in kids)

## **Chronic Migraine**

- At least 15 HA days per month for more than 3 months
- Migraine features at least 8 days per month

# Migraine Subtypes

- · Migraine with Aura
  - 14-30% children report aura
  - Typical aura

25

- Visual, sensory, and/or speech/language
- No motor weakness
- · Gradual development
- Typically no longer than 1 hour
- · Complete reversibility
- Hemiplegic migraine
  - Sporadic vs. familial

26

2

## Migraine Subtypes

- · Migraine with Aura
  - Vestibular migraine
    - Any age
    - Severe vertigo/dizziness
    - 5-72 hours

## Migraine Subtypes

Migraine Subtypes

• Vertigo, dysarthria, tinnitus, diplopia, bilateral visual

symptoms, bilateral paresthesias, decreased LOC,

Migraine with aura

· Migraine with Aura

- Brainstem aura

• Females>Males

• 7-20 years of age

No motor weakness

hypacusis

• Rare

- Retinal/ocular migraine
  - Rare
  - Sudden loss of vision, photopsia, or scintillations in only one eye
  - 5-60 minutes
  - May occur with or without HA, typically uni-ocular
  - Permanent vision loss may occur
  - Fundoscopy: retina pale, constricted vessels
- Menstrual migraine

27 28

## Migraine Equivalents/Variants

- · Cyclic vomiting syndrome
- · Abdominal migraine
- · Benign paroxysmal vertigo
- · Benign paroxysmal torticollis
- · Colic?
- · Acute confusional migraine
- Alice in Wonderland syndrome
- Opthalmoplegic migraine

## Migraine Complications

- Status migrainosus: attack lasting >72 hrs
- · Persistent aura without infarction
- · Migrainous infarction (neuroimaging)
- Migraine aura-triggered seizure

## Migraine Treatment

# Lifestyle Modifications

- Education
- · Good sleep hygiene
- · Adequate water intake
- · Routine, healthy meals and snacks
- · Regular exercise
- Avoid migraine triggers
- · Limit caffeine intake

31 32

#### **Preventative Medications**

- Indications
  - Frequent or long lasting
  - Significant disability or diminished quality of life
  - Contraindication, failure of, or adverse effects of acute therapies
  - Medication overuse HA
  - Menstrual migraine

#### **Preventative Medications**

- · Duration of treatment
  - 6-8 weeks at therapeutic doses for full benefit
  - 6-12 months of good headache control before discontinuing therapy

33

#### **Preventative Medications**

- CHAMP trial: placebo is as effective and better tolerated than amitriptyline or topiramate
- Nutraceuticals
  - Riboflavin (Migrelief: 0.5-1 tab BID)
    - Bright yellow/orange urine
    - Gl upset uncommon
  - Melatonin (1-3 mg qhs, max 9 mg qhs)
    - Daytime sleepiness
  - Magnesium, feverfew, coenzyme Q10, butterbur, ginkolide B, polyunsaturated fats

## **Preventative Medications**

Cyproheptadine

34

- 2-4 mg qhs; max 16 mg per day, divided BID
- Liquid or tablet
- Appetite stimulation
- Somnolence

# Preventative Medications: Tricyclics

- · Amitriptyline
  - 5-12.5 mg qhs, max 2 mg/kg/day or 100 mg qhs
  - Sedating
  - Tachychardia
  - Prolongation of QT interval
    - EKG at baseline and higher doses
- Nortriptyline
  - Less sedating
- Trazodone

38

37 38

# Preventative Medications: Antiseizure Medications

- Valproate
  - 10-15 mg/kg/day divided BID
  - Weight gain, hepatotoxicity (<2 yrs), thombocytopenia
  - Teratogenic
  - CBC, AST, ALT
- Gabapentin
  - TID dosing
- Restless leg syndrome or neuropathic pain
- Levetiracetam

# Preventative Medications: Beta Blockers

**Preventative Medications:** 

**Antiseizure Medications** 

 Weight loss, cognitive impairment, paresthesias, closed-angle glaucoma, hypohydrosis,

- 1-2 mg/kg/day, max 50 mg BID

- Potentially lowers efficacy of OCP's

Propranolol

Topiramate

nephrolithiasis

Teratogenicity and LBW

- 1 mg/kg/day divided TID (multiple doses per day)
- Abdominal migraines, anxiety, tremor
- Hypotension, bradycardia, emotional disturbances, nightmares
- Monitor HR and orthostatic BP (tall/skinny/active patients)
- Use caution in patients with asthma, diabetes, depression
- · Propranolol LA
- Atenolol

40

 Beta-1 selective blocker, can be safer than nonselective beta blockers (propranolol)

39

## Neurostimulation

- Trancutaneous electrical nerve stimulation (TENS)
  - Cefaly device
  - Preventative and acute treatment
  - Drowsiness, well tolerated
  - Costs ~\$500, insurance typically doesn't cover

## Neurostimulation

- Remote Electrical Neuromodulation (REN)
  - Nerivio device
  - Stimulates nociceptive nerve in the upper arm→ sends messages to the pain regulation centers in the brainstem→ activates the descending pain inhibitory pathways→ serotonin and norepinephrine are released
  - Preventative and acute treatment
  - Temporary warm sensation, tingling, numbness, or pain in the arm, red skin, or muscle spasm (2% or less)
  - FDA approved 8 years and older

### Neurostimulation

- Transcranial magnetic stimulation
  - 0.9 Tesla magnetic field in a brief pulse over occipital area
  - Preventative and acute treatment
  - Can cost up to \$12,000, \$500 per session, several sessions over multiple weeks

#### Botulinum toxin

- Shown to decrease number of headache days in adults with chronic migraine
- Retrospective studies in children show similar results, clinical trial recently showed no benefit
- IM injections every 12 weeks
- Neck/musculoskeletal pain, facial drooping
- Must fail 2-3 prescription medications
- Yearly cost \$14K, typically well covered by insurance

43 44

## **CGRP Antagonists**

- CGRP: found in unmyelinated sensory nerve fibers
  - Associated with transmission of painful stimuli
- Monoclonal antibodies to CGRP or its receptor have been shown to be effective in adults
- MOST not approved for <18 years</li>
  - Poorly covered by insurance, yearly cost >\$7K
  - Exc. AJOVY approved for 6-17 years, 45 kilograms (99 pounds) or more.

## Other Preventative Treatments

- · Behavioral therapy
  - Cognitive behavioral therapy
    - Clinical trial showed benefit in children with CBT+amitriptyline vs. HA education+amitriptyline
    - Comorbid anxiety and depression VERY common
  - Biofeedback
  - Limitations: availability, cost, patient ability and compliance

45 46

## Other Preventative Treatments

- Physical therapy
  - Chronic migraine
  - Head injury/concussion
  - Other comorbidities

#### Other Preventative Treatments

- Other
  - Chiropractics
  - Massage therapy
  - Acupuncture/acupressure
  - Daith piercing
  - CBD and medical marijuana
  - Hyperbaric chamber

# Menstrual Migraine

- · Migrelief+M
- Hormonal therapy
- · "Mini-prophylaxis"
  - 1-2 days prior to expected headache onset
  - Continued for expected duration
  - Naproxen 550 mg BID
  - Long acting triptans

#### **Acute Treatment**

- General measures
  - Dark, quiet room
  - Cool cloth applied to forehead
- NEVER USE:
  - Opioids
  - Barbituates
  - Benzodiazepines

49

## **Acute Treatment**

- Analgesics
  - Ibuprofen 10 mg/kg or acetaminophen 15 mg/kg
    - Onset of migraine symptoms, can repeat in 2 hours
  - Naproxen 5 mg/kg every 8-12 hours
  - Excedrin Migraine 1 tablet
    - Adolescents only due to aspirin
  - No more than 2 doses per day, 2 days per week
  - Can take with caffeine.

**Acute Treatment** 

Triptans

50

- 5 years of age and older
- Refractory to analgesics
- Onset of migraine symptoms, can repeat in 2 hours
- No more than 2 doses per day, 2 days per week
- Can take with caffeine

51 52

#### **Acute Treatment**

- Triptans
  - Sumatriptan 25-50 mg oral, 5-10 mg nasal
  - Rizatriptan 2.5-5 mg oral or dissolvable
  - Zolmitriptan 2.5-5 mg oral, dissolvable, or nasal
- Nasal sprays: tilt head forward, hard candy
- Contraindications: Hx ischemic vascular disease or arrhythmias a/w accessory conduction pathway d/o's
- Caution: brainstem aura and hemiplegic migraine

**Acute Treatment** 

- Combination
  - Same time: triptan + naproxen
  - Severity based: analgesic mild to mod, triptan severe
- Antiemetics
  - Promethazine 0.25-0.5 mg/kg per dose
  - Ondansetron 4 mg every 8 hours

# Status Migrainosus

- · Clinic/Urgent Care
  - Ketorolac 15-60 mg IM + antiemetic
- · Emergency setting
  - IV fluids 20 mL/kg NS, max 1 L
  - IV ketorolac
  - IV antiemetic (ex. Prochlorperazine)
- DHE: caution with brainstem aura and hemiplegic migraine
- IV valproate

## **Prognosis**

- · Many patients improve over time
  - Rule of thirds
- Girls more likely to relapse
- Early age may mean a less favorable prognosis

55

56

#### Resources

- Abu-Arafeh I, Razak S, Sivaraman B, Graham C. Prevalence of headache and migraine in children and adolescents: a systematic review of population-based studies. Dev Med Child Neurol 2010; 52:1088.
- Cefaly. https://www.cefaly.com
- <u>El-Chammas K, Keyes J, Thompson N, et al. Pharmacologic treatment of pediatric headaches: a meta-analysis. JAMA Pediatr 2013; 167:250.</u>
- Headache Classification Committee of the International Headache Society (IHS)
   The International Classification of Headache Disorders, 3rd edition. Cephalalgia 2018: 38:1
- Nerivio. <a href="https://www.nerivio.com">https://www.nerivio.com</a>
- Oskoui M, Pringsheim T, Holler-Managan Y, et al. Practice guideline update summary: Acute treatment of migraine in children and adolescents: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology 2019; 93:487.

Resources

- UpToDate. https://www.uptodate.com
- Powers SW, Coffey CS, Chamberlin LA, et al. Trial of Amitriptyline, Topiramate, and Placebo for Pediatric Migraine. N Engl J Med 2017; 376:115.
- Silberstein SD. Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000; 55:754.
- US Headache Consortium. Evidence-based guidelines in the primary care setting: Neuroimaging in patients with nonacute headache, 2000.
   <a href="https://www.aan.com/professionals/practice/pdfs/gl0088.pdf">www.aan.com/professionals/practice/pdfs/gl0088.pdf</a>

57

58

# Questions?